Contineum Therapeutics (CTNM) Projected to Post Earnings on Wednesday

Key Points

• Contineum Therapeutics (CTNM) is scheduled to report Q1 2026 results before the market opens on Wednesday, May 13, with analysts forecasting a loss of ($0.55) per share; the company last reported ($0.39) EPS, beating the prior consensus by $0.16.
• Shares opened at $14.39, trade between a 52‑week low/high of $3.35/$16.33, and the company has a market cap of about $537.3 million with a negative P/E of -6.6.
• Analyst coverage is mixed but the consensus is a "Moderate Buy" with a target price of $19.50, reflecting four Buy, one Hold and one Sell ratings and recent divergent moves from firms like Morgan Stanley and Robert W. Baird.

Contineum Therapeutics (NASDAQ:CTNM - Get Free Report) is expected to post its Q1 2026 results before the market opens on Wednesday, May 13th. Analysts expect Contineum Therapeutics to post earnings of ($0.55) per share for the quarter. Investors are encouraged to explore the company's upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Tuesday, May 5, 2026 at 4:00 PM ET.

Contineum Therapeutics (NASDAQ:CTNM - Get Free Report) last issued its quarterly earnings results on Tuesday, May 5th. The company reported ($0.39) EPS for the quarter, topping the consensus estimate of ($0.55) by $0.16. On average, analysts expect Contineum Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Contineum Therapeutics Stock Performance

Shares of CTNM stock opened at $14.39 on Wednesday. Contineum Therapeutics has a fifty-two week low of $3.35 and a fifty-two week high of $16.33. The stock's fifty day moving average is $13.46 and its two-hundred day moving average is $12.55. The firm has a market capitalization of $537.32 million, a P/E ratio of -6.60 and a beta of 0.89.

Analyst Upgrades and Downgrades

CTNM has been the subject of a number of recent research reports. Morgan Stanley reiterated an "equal weight" rating and issued a $14.00 target price (down from $23.00) on shares of Contineum Therapeutics in a research report on Thursday, January 8th. Weiss Ratings restated a "sell (d-)" rating on shares of Contineum Therapeutics in a research report on Monday, April 20th. Wall Street Zen lowered shares of Contineum Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, March 7th. Finally, Robert W. Baird boosted their price target on shares of Contineum Therapeutics from $14.00 to $20.00 and gave the stock an "outperform" rating in a research report on Friday, March 6th. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $19.50.

Institutional Trading of Contineum Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of CTNM. Strs Ohio acquired a new stake in shares of Contineum Therapeutics during the first quarter worth about $27,000. Qube Research & Technologies Ltd acquired a new position in shares of Contineum Therapeutics in the second quarter valued at approximately $43,000. Marex Group plc purchased a new stake in Contineum Therapeutics during the 2nd quarter worth approximately $45,000. Bridgeway Capital Management LLC acquired a new stake in Contineum Therapeutics during the 2nd quarter worth approximately $76,000. Finally, Jane Street Group LLC acquired a new stake in Contineum Therapeutics during the 2nd quarter worth approximately $81,000.

Contineum Therapeutics Company Profile

Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.